New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 28, 2012
07:34 EDTCPHDCepheid 2013 sales of CT/NG estimated $15M-$20M at William Blair
William Blair expects solid initial demand for Cepheid's just approved Xpert CT/NG from existing Xpert customers and projects 2013 sales between $15M-$20M on a worldwide basis. However, William Blair says it is not sure if Cepheid will be able to ship enough product to meet initial demand as it provided no update on the recent manufacturing issues. The firm keeps an Outperform rating on the stock.
News For CPHD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 2, 2015
10:04 EDTCPHDCepheid issued a long-term Sell rating at Off Wall Street Research
Subscribe for More Information
June 26, 2015
10:00 EDTCPHDOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:05 EDTCPHDCepheid upgraded to Buy from Hold at Craig-Hallum
Craig-Hallum upgraded Cepheid to Buy and raised its price target to $75 from $52. The firm said Cepheid is rapidly expanding its clinical offering and customer reach and is emerging as the leading platform for molecular diagnostics.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use